Fig. 2: Nuclear TG2 interacts with IRF3 covalent dimers.
From: Transglutaminase type 2-dependent crosslinking of IRF3 in dying melanoma cells

Western blot analysis showing cytosolic (A) and nuclear (B) protein expression of TG2 and IRF3 in A375 cells treated with doxorubicin for 16 h. GAPDH and TBP were used as loading control for cytosolic and nuclear fraction respectively. (n = 3; means ± SEM; **p < 0.01; ***p < 0.001). C Western blot showing nuclear TG2 co-immunoprecipitation in A375 treated with doxorubicin for 16 h. D Western blot showing nuclear IRF3 co-immunoprecipitation in A375 treated with doxorubicin for 16 h.